Premium
Low‐molecular contrast agent dynamic contrast‐enhanced (DCE)‐MRI and diffusion‐weighted (DW)‐MRI in early assessment of bevacizumab treatment in breast cancer xenografts
Author(s) -
Moestue Siver A.,
Huuse Else M.,
Lindholm Evita M.,
Bofin Anna,
Engebraaten Olav,
Mælandsmo Gunhild M.,
Akslen Lars A.,
Gribbestad Ingrid S.
Publication year - 2013
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.24079
Subject(s) - bevacizumab , medicine , magnetic resonance imaging , dynamic contrast enhanced mri , breast cancer , diffusion mri , doxorubicin , effective diffusion coefficient , nuclear medicine , dynamic contrast , basal (medicine) , breast mri , pathology , cancer , chemotherapy , radiology , mammography , insulin
Purpose To investigate the effect of bevacizumab treatment on vascular architecture and function in two xenograft models with different angiogenic properties using diffusion‐weighted magnetic resonance imaging (DW‐MRI) and dynamic contrast‐enhanced MRI (DCE‐MRI). Materials and Methods Mice carrying basal‐like (MAS98.12) or luminal‐like (MAS98.06) orthotopic breast cancer xenografts were treated with bevacizumab (5 mg/kg), doxorubicin (8 mg/kg), or both drugs in combination. DW‐MRI and DCE‐MRI were performed before and 3 days after treatment using a Bruker 7T preclinical scanner. Mean microvessel density (MVD) and proliferating microvessel density (pMVD) in the tumors were determined for evaluation of vascular response to bevacizumab treatment. Results No changes in DCE‐MRI or DW‐MRI parameters were observed in untreated controls during the experiment period. DW‐MRI showed increased apparent diffusion coefficient (ADC) values in all treatment groups in both basal‐like and luminal‐like xenografts. DCE‐MRI showed increased contrast agent uptake, particularly in central regions of the tumors, after bevacizumab/combination treatment in both xenograft models. This was accompanied by decreased MVD and pMVD in basal‐like xenografts. Doxorubicin treatment had no effect on DCE‐MRI parameters in any of the xenograft models. Conclusion Both DW‐MRI and DCE‐MRI demonstrated an early response to bevacizumab treatment in the xenograft tumors. Increased contrast agent uptake and reduced MVD/pMVD is consistent with a normalization of vascular function. J. Magn. Reson. Imaging 2013;38:1043–1053. © 2013 Wiley Periodicals, Inc.